Real-world data of anamorelin in advanced gastrointestinal cancer patients with cancer cachexia.
Anamorelin
Anorexia
Body weight
Body weight loss
Cachexia
Gastrointestinal cancer
Journal
BMC palliative care
ISSN: 1472-684X
Titre abrégé: BMC Palliat Care
Pays: England
ID NLM: 101088685
Informations de publication
Date de publication:
24 Aug 2024
24 Aug 2024
Historique:
received:
20
12
2023
accepted:
30
07
2024
medline:
26
8
2024
pubmed:
26
8
2024
entrez:
24
8
2024
Statut:
epublish
Résumé
Cancer cachexia is characterized by the loss of body weight (BW) and anorexia. Anamorelin (ANAM) is a selective ghrelin receptor agonist with appetite-enhancing anabolic action. The ONO-7643-05 trial demonstrated that ANAM increased lean body mass and improved anorexia in a Japanese population. However, the clinical outcomes of patients on ANAM have not yet been reported. We investigated the clinical outcomes of patients with unresectable, advanced, or recurrent gastrointestinal cancer (colorectal, gastric, or pancreatic cancer) who were treated with ANAM between April 2017 and August 2022. Cachexia was defined as the presence of anorexia and a loss of ≥ 5% of BW within 6 months. To evaluate the response to ANAM, the patients who had discontinued ANAM within 3 weeks were excluded. Response to ANAM was defined as maintenance of or increase in BW and improved appetite from baseline at every 3-week evaluation. We also collected data on the reasons for the discontinuation of ANAM and the correlation between clinical factors and ANAM response. Safety analysis of ANAM was performed for all patients who received ANAM. Seventy-four patients were included in this study (49 males and 25 females), with a median age of 67.1 years (range, 36-83). The primary tumors were colorectal cancer in 27 (36.5%), gastric cancer in 20 (27.0%), and pancreatic cancer in 27 (36.5%). The Eastern Cooperative Oncology Group performance status was 0 in 10 (13.5%), 1 in 44 (59.5%), and ≥ 2 in 20 (27.0%). The number of previous chemotherapy regimens was 0 in 20 (27.0%), 1 in 22 (29.7%), and ≥ 2 in 32 (43.2%). ANAM was discontinued within 3 weeks in 28 patients for the following reasons: low-grade (grade 1 or 2) adverse events in 15 patients, ileus in three, grade 3 fatigue in one, progressive disease in one, censored follow-up in six, and unknown reasons in three. The proportion of ANAM responders was 63.6% (95% confidence interval, 47.8-77.6%). Among baseline characteristics, age ≥ 75 attenuated the ANAM response (p = 0.03). ANAM responders showed better disease control with chemotherapy than non-responders (75.0% vs. 37.5%, p = 0.02). ANAM may improve the outcomes of patients with gastrointestinal cancer cachexia in clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer cachexia is characterized by the loss of body weight (BW) and anorexia. Anamorelin (ANAM) is a selective ghrelin receptor agonist with appetite-enhancing anabolic action. The ONO-7643-05 trial demonstrated that ANAM increased lean body mass and improved anorexia in a Japanese population. However, the clinical outcomes of patients on ANAM have not yet been reported.
PATIENTS AND METHODS
METHODS
We investigated the clinical outcomes of patients with unresectable, advanced, or recurrent gastrointestinal cancer (colorectal, gastric, or pancreatic cancer) who were treated with ANAM between April 2017 and August 2022. Cachexia was defined as the presence of anorexia and a loss of ≥ 5% of BW within 6 months. To evaluate the response to ANAM, the patients who had discontinued ANAM within 3 weeks were excluded. Response to ANAM was defined as maintenance of or increase in BW and improved appetite from baseline at every 3-week evaluation. We also collected data on the reasons for the discontinuation of ANAM and the correlation between clinical factors and ANAM response. Safety analysis of ANAM was performed for all patients who received ANAM.
RESULTS
RESULTS
Seventy-four patients were included in this study (49 males and 25 females), with a median age of 67.1 years (range, 36-83). The primary tumors were colorectal cancer in 27 (36.5%), gastric cancer in 20 (27.0%), and pancreatic cancer in 27 (36.5%). The Eastern Cooperative Oncology Group performance status was 0 in 10 (13.5%), 1 in 44 (59.5%), and ≥ 2 in 20 (27.0%). The number of previous chemotherapy regimens was 0 in 20 (27.0%), 1 in 22 (29.7%), and ≥ 2 in 32 (43.2%). ANAM was discontinued within 3 weeks in 28 patients for the following reasons: low-grade (grade 1 or 2) adverse events in 15 patients, ileus in three, grade 3 fatigue in one, progressive disease in one, censored follow-up in six, and unknown reasons in three. The proportion of ANAM responders was 63.6% (95% confidence interval, 47.8-77.6%). Among baseline characteristics, age ≥ 75 attenuated the ANAM response (p = 0.03). ANAM responders showed better disease control with chemotherapy than non-responders (75.0% vs. 37.5%, p = 0.02).
CONCLUSIONS
CONCLUSIONS
ANAM may improve the outcomes of patients with gastrointestinal cancer cachexia in clinical practice.
Identifiants
pubmed: 39182074
doi: 10.1186/s12904-024-01538-9
pii: 10.1186/s12904-024-01538-9
doi:
Substances chimiques
anamorelin
DD5RBA1NKF
Oligopeptides
0
Hydrazines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
214Informations de copyright
© 2024. The Author(s).
Références
Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95. https://doi.org/10.1016/S1470-2045(10)70218-7 .
doi: 10.1016/S1470-2045(10)70218-7
pubmed: 21296615
Donohoe CL, Ryan AM, Reynolds JV. Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract. 2011;2011:601434. https://doi.org/10.1155/2011/601434 .
doi: 10.1155/2011/601434
pubmed: 21760776
pmcid: 3132494
Argilés JM, Busquets S, Toledo M, López-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care. 2009;3:263–8. https://doi.org/10.1097/SPC.0b013e3283311d09 .
doi: 10.1097/SPC.0b013e3283311d09
pubmed: 19713854
Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013;10:90–9. https://doi.org/10.1038/nrclinonc.2012.209 .
doi: 10.1038/nrclinonc.2012.209
pubmed: 23207794
Todorov PT, Field WN, Tisdale MJ. Role of a proteolysis-inducing factor (PIF) in cachexia induced by a human melanoma (G361). Br J Cancer. 1999;80:1734–7. https://doi.org/10.1038/sj.bjc.6690590 .
doi: 10.1038/sj.bjc.6690590
pubmed: 10468289
pmcid: 2374268
Beck SA, Tisdale MJ. Lipid mobilising factors specifically associated with cancer cachexia. Br J Cancer. 1991;63:846–50. https://doi.org/10.1038/bjc.1991.188 .
doi: 10.1038/bjc.1991.188
pubmed: 2069843
pmcid: 1972519
Argilés JM, Busquets S, Stemmler B, López-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014;14:754–62. https://doi.org/10.1038/nrc3829 .
doi: 10.1038/nrc3829
pubmed: 25291291
Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21:1569–77. https://doi.org/10.1007/s00520-012-1697-z .
doi: 10.1007/s00520-012-1697-z
pubmed: 23314651
Von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J cachexia Sarcopenia Muscle. 2010;1:1–5. https://doi.org/10.1007/s13539-010-0002-6 .
doi: 10.1007/s13539-010-0002-6
Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9. https://doi.org/10.1016/s0959-8049(97)10090-9 .
doi: 10.1016/s0959-8049(97)10090-9
pubmed: 9713300
Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle. 2013;4:95–109. https://doi.org/10.1007/s13539-012-0087-1 .
doi: 10.1007/s13539-012-0087-1
pubmed: 23097000
Hopkinson JB. Psychosocial impact of cancer cachexia. J Cachexia Sarcopenia Muscle. 2014;5:89–94. https://doi.org/10.1007/s13539-014-0142-1 .
doi: 10.1007/s13539-014-0142-1
pubmed: 24737110
pmcid: 4053560
Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. East Coop Oncol Group Am J Med. 1980;69:491–7. https://doi.org/10.1016/s0149-2918(05)80001-3 .
doi: 10.1016/s0149-2918(05)80001-3
Fox KM, Brooks JM, Gandra SR, et al. Estimation of Cachexia among Cancer patients based on four definitions. J Oncol. 2009;2009:693458. https://doi.org/10.1155/2009/693458 .
doi: 10.1155/2009/693458
pubmed: 19587829
pmcid: 2705834
Sun L, Quan X-Q, Yu S. An epidemiological survey of Cachexia in Advanced Cancer patients and Analysis on its Diagnostic and Treatment Status. Nutr Cancer. 2015;67:1056–62. https://doi.org/10.1080/01635581.2015.1073753 .
doi: 10.1080/01635581.2015.1073753
pubmed: 26317149
Hamauchi S, Furuse J, Takano T, et al. A multicenter, open-label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 2019;125:4294–302. https://doi.org/10.1002/cncr.32406 .
doi: 10.1002/cncr.32406
pubmed: 31415709
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026 .
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Common Terminology Criteria for Adverse Events (CTCAE). Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244 .
doi: 10.1038/bmt.2012.244
Namikawa T, Marui A, Yokota K, et al. Frequency and prognostic impact of cachexia during drug treatment for unresectable advanced gastric cancer patients. Surg Today. 2022;52:1560–7. https://doi.org/10.1007/s00595-022-02493-9 .
doi: 10.1007/s00595-022-02493-9
pubmed: 35322296
Fukahori M, Shibata M, Hamauchi S, et al. A retrospective cohort study to investigate the incidence of cancer-related weight loss during chemotherapy in gastric cancer patients. Support Care Cancer. 2021;29:341–8. https://doi.org/10.1007/s00520-020-05479-w .
doi: 10.1007/s00520-020-05479-w
pubmed: 32361831
Mitsunaga S, Kasamatsu E, Machii K. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Support Care Cancer. 2020;28:5271–9. https://doi.org/10.1007/s00520-020-05346-8 .
doi: 10.1007/s00520-020-05346-8
pubmed: 32103356
pmcid: 7546994
Kordes M, Larsson L, Engstrand L, Löhr J-M. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Br J Cancer. 2021;124:1623–36. https://doi.org/10.1038/s41416-021-01301-4 .
doi: 10.1038/s41416-021-01301-4
pubmed: 33742145
pmcid: 8110983
Takeda T, Sasaki T, Okamoto T, et al. Impact of the extent of weight loss before Administration on the efficacy of Anamorelin in Advanced Pancreatic Cancer patients with Cachexia. Intern Med. 2023;62:1887–93. https://doi.org/10.2169/internalmedicine.0730-22 .
doi: 10.2169/internalmedicine.0730-22
pubmed: 36418096
Ando K, Naito T, Hamauchi S, et al. The efficacy and safety of anamorelin among patients with diabetes. Int J Clin Oncol. 2024. https://doi.org/10.1007/s10147-024-02546-8 .
doi: 10.1007/s10147-024-02546-8
pubmed: 38722487